uniQure (QURE) Long-Term Debt Issuances (2021)
uniQure (QURE) posted quarterly Long-Term Debt Issuances of $29.5 million for Q4 2021, up 2355.33% quarter-over-quarter from $1.2 million in Q3 2021.
Powered by 
Analysis
uniQure (QURE) Long-Term Debt Issuances (2021) Analysis & Trends
uniQure's Long-Term Debt Issuances history runs 1 years deep, the most recent figure standing at $29.5 million for Q4 2021.
- In Q4 2021, Long-Term Debt Issuances changed N/A year-over-year to $29.5 million; the TTM figure through Sep 2021 stood at $1.2 million (changed N/A YoY), while the FY2021 annual figure was $64.1 million, changed N/A from the prior year.
- Long-Term Debt Issuances for Q4 2021 stood at $29.5 million, up from $1.2 million in the prior quarter.
- The five-year high for Long-Term Debt Issuances was $34.6 million in Q1 2021, with the low at $1.2 million in Q3 2021.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Long-Term Debt Issuances (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | - |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | - |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | - |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | - |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | - |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | - |
| 10 | uniQure | 2.95 Bn | 2.95 Bn | 5.49 Mn | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Dec 31, 2021 | 29.46 Mn |
| Sep 30, 2021 | 1.20 Mn |
| Mar 31, 2021 | 34.60 Mn |